Pediatric Nephrology

, Volume 25, Issue 9, pp 1607–1620 | Cite as

The virtues of vitamin D—but how much is too much?

  • Rukshana Shroff
  • Craig Knott
  • Lesley Rees


Vitamin D deficiency is common in healthy adults and children as well as in the chronic kidney disease (CKD) population. What was once a disease of malnourished children in the developing world has re-emerged and reached pandemic proportions. In parallel with this development, there is a growing awareness that vitamin D is not simply a ‘calcaemic hormone’ but plays an important role in the prevention of cardiovascular disease, infectious and auto-immune conditions, renoprotection, glycaemic control and prevention of some common cancers. Most tissues in the body have a vitamin D receptor and the enzymatic machinery to convert ‘nutritional’ 25-hydroxyvitamin D to the active form 1,25-dihydroxyvitamin D; it is estimated that 3% of the human genome is regulated by the vitamin D endocrine system. Although there are few well-conducted studies on the benefits of vitamin D therapy, an exuberant use of vitamin D is now seen in the general population and at all stages of CKD. There is emerging evidence that vitamin D may in fact have a therapeutic window, and at least from the effects on the cardiovascular system, more is not necessarily better. In this review, we discuss the role of nutritional vitamin D (ergocalciferol or cholecalciferol) supplementation in CKD patients, interpreting the clinical studies in the light of the vitamin D metabolic pathway and its pluripotent effects. While nutritional vitamin D compounds clearly have numerous beneficial effects, randomised controlled studies are required to determine the effectiveness and optimal dose at different stages of CKD, its concurrent use with activated vitamin D compounds and its safety profile.


Children Cholecalciferol Chronic kidney disease Ergocalciferol Vitamin D 


  1. 1.
    Holick MF (2007) Vitamin D deficiency. N Engl J Med 357:266–281PubMedCrossRefGoogle Scholar
  2. 2.
    Zittermann A (2003) Vitamin D in preventive medicine: are we ignoring the evidence? Br J Nutr 89:552–572PubMedCrossRefGoogle Scholar
  3. 3.
    Holick MF, Frommer JE, McNeill SC, Richtand NM, Henley JW, Potts JT Jr (1977) Photometabolism of 7-dehydrocholesterol to previtamin D3 in skin. Biochem Biophys Res Commun 76:107–114PubMedCrossRefGoogle Scholar
  4. 4.
    Holick MF, MacLaughlin JA, Clark MB, Holick SA, Potts JT Jr, Anderson RR, Blank IH, Parrish JA, Elias P (1980) Photosynthesis of previtamin D3 in human skin and the physiologic consequences. Science 210:203–205PubMedCrossRefGoogle Scholar
  5. 5.
    Holick MF (2005) Vitamin D for health and in chronic kidney disease. Semin Dial 18:266–275PubMedCrossRefGoogle Scholar
  6. 6.
    Lips P (2007) Vitamin D status and nutrition in Europe and Asia. J Steroid Biochem Mol Biol 103:620–625PubMedCrossRefGoogle Scholar
  7. 7.
    Lips P, Bouillon R, van Schoor NM, Vanderschueren D, Verschueren S, Kuchuk N, Milisen K, Boonen S (2009) Reducing fracture risk with calcium and vitamin D. Clin Endocrinol (Oxf). doi: 10.1111/j.0300-0664.2009.03701.x Google Scholar
  8. 8.
    Dusso AS, Brown AJ, Slatopolsky E (2005) Vitamin D. Am J Physiol Renal Physiol 289:F8–F28PubMedCrossRefGoogle Scholar
  9. 9.
    Gascon-Barre M (2005) The vitamin D 25-hydroxylase. In: Feldman D, Pike F, Glorieux JW (eds) Vitamin D, 2nd edn. Amsterdam, ElsevierGoogle Scholar
  10. 10.
    Jones G (2008) Pharmacokinetics of vitamin D toxicity. Am J Clin Nutr 88:582S–586SPubMedGoogle Scholar
  11. 11.
    Andress DL (2006) Vitamin D in chronic kidney disease: a systemic role for selective vitamin D receptor activation. Kidney Int 69:33–43PubMedCrossRefGoogle Scholar
  12. 12.
    Bikle D (2009) Nonclassic actions of vitamin D. J Clin Endocrinol Metab 94:26–34PubMedCrossRefGoogle Scholar
  13. 13.
    Shimada T, Kakitani M, Yamazaki Y, Hasegawa H, Takeuchi Y, Fujita T, Fukumoto S, Tomizuka K, Yamashita T (2004) Targeted ablation of Fgf23 demonstrates an essential physiological role of FGF23 in phosphate and vitamin D metabolism. J Clin Invest 113:561–568PubMedGoogle Scholar
  14. 14.
    Gutierrez O, Isakova T, Rhee E, Shah A, Holmes J, Collerone G, Juppner H, Wolf M (2005) Fibroblast growth factor-23 mitigates hyperphosphatemia but accentuates calcitriol deficiency in chronic kidney disease. J Am Soc Nephrol 16:2205–2215PubMedCrossRefGoogle Scholar
  15. 15.
    Wong YF, Xu Q (2009) Ablation of klotho and premature aging: is 1, 25-dihydroxyvitamin D the key middleman? Kidney Int 75:1137–1139PubMedCrossRefGoogle Scholar
  16. 16.
    Bouillon R, Norman AW, Lips P (2007) Vitamin D deficiency. N Engl J Med 357:1980–1981PubMedCrossRefGoogle Scholar
  17. 17.
    Dusso AS, Finch J, Brown A, Ritter C, Delmez J, Schreiner G, Slatopolsky E (1991) Extrarenal production of calcitriol in normal and uremic humans. J Clin Endocrinol Metab 72:157–164PubMedCrossRefGoogle Scholar
  18. 18.
    Haussler MR, Whitfield GK, Haussler CA, Hsieh JC, Thompson PD, Selznick SH, Dominguez CE, Jurutka PW (1998) The nuclear vitamin D receptor: biological and molecular regulatory properties revealed. J Bone Miner Res 13:325–349PubMedCrossRefGoogle Scholar
  19. 19.
    Valdivielso JM (2009) The physiology of vitamin D receptor activation. Contrib Nephrol 163:206–212PubMedCrossRefGoogle Scholar
  20. 20.
    Klaus G (2008) Renoprotection with vitamin D: specific for diabetic nephropathy? Kidney Int 73:141–143PubMedCrossRefGoogle Scholar
  21. 21.
    Zhang Z, Zhang Y, Ning G, Deb DK, Kong J, Li YC (2008) Combination therapy with AT1 blocker and vitamin D analog markedly ameliorates diabetic nephropathy: blockade of compensatory renin increase. Proc Natl Acad Sci USA 105:15896–15901PubMedCrossRefGoogle Scholar
  22. 22.
    Brown AJ (2007) Vitamin D analogs for secondary hyperparathyroidism: what does the future hold? J Steroid Biochem Mol Biol 103:578–583PubMedCrossRefGoogle Scholar
  23. 23.
    Correa P, Segersten U, Hellman P, Akerstrom G, Westin G (2002) Increased 25-hydroxyvitamin D3 1alpha-hydroxylase and reduced 25-hydroxyvitamin D3 24-hydroxylase expression in parathyroid tumors–new prospects for treatment of hyperparathyroidism with vitamin d. J Clin Endocrinol Metab 87:5826–5829PubMedCrossRefGoogle Scholar
  24. 24.
    Gonzalez EA, Sachdeva A, Oliver DA, Martin KJ (2004) Vitamin D insufficiency and deficiency in chronic kidney disease. A single center observational study. Am J Nephrol 24:503–510PubMedCrossRefGoogle Scholar
  25. 25.
    Rees L (2008) What parathyroid hormone levels should we aim for in children with stage 5 chronic kidney disease; what is the evidence? Pediatr Nephrol 23:179–184PubMedCrossRefGoogle Scholar
  26. 26.
    Lips P (2006) Vitamin D physiology. Prog Biophys Mol Biol 92:4–8PubMedCrossRefGoogle Scholar
  27. 27.
    Rostand SG, Drueke TB (1999) Parathyroid hormone, vitamin D, and cardiovascular disease in chronic renal failure. Kidney Int 56:383–392PubMedCrossRefGoogle Scholar
  28. 28.
    Mathew S, Lund RJ, Chaudhary LR, Geurs T, Hruska KA (2008) Vitamin D receptor activators can protect against vascular calcification. J Am Soc Nephrol 19:1509–1519PubMedCrossRefGoogle Scholar
  29. 29.
    Dusso A, Finch J, Delmez J, Rapp N, Lopez-Hilker S, Brown A, Slatopolsky E (1990) Extrarenal production of calcitriol. Kidney Int Suppl 29:S36–S40PubMedGoogle Scholar
  30. 30.
    van DM, Koedam M, Buurman CJ, Hewison M, Chiba H, Uitterlinden AG, Pols HA, van Leeuwen JP (2006) Evidence for auto/paracrine actions of vitamin D in bone: 1alpha-hydroxylase expression and activity in human bone cells. FASEB J 20:2417–2419CrossRefGoogle Scholar
  31. 31.
    Cranney A, Horsley T, O’Donnell S, Weiler H, Puil L, Ooi D, Atkinson S, Ward L, Moher D, Hanley D, Fang M, Yazdi F, Garritty C, Sampson M, Barrowman N, Tsertsvadze A, Mamaladze V (2007) Effectiveness and safety of vitamin D in relation to bone health. Evid Rep Technol Assess (Full Rep) 158:1–235Google Scholar
  32. 32.
    Geary DF, Hodson EM, Craig JC (2010) Interventions for bone disease in children with chronic kidney disease. Cochrane Database Syst Rev CD008327Google Scholar
  33. 33.
    Shoben AB, Rudser KD, de Boer IH, Young B, Kestenbaum B (2008) Association of oral calcitriol with improved survival in nondialyzed CKD. J Am Soc Nephrol 19:1613–1619Google Scholar
  34. 34.
    Shoji T, Shinohara K, Kimoto E, Emoto M, Tahara H, Koyama H, Inaba M, Fukumoto S, Ishimura E, Miki T, Tabata T, Nishizawa Y (2004) Lower risk for cardiovascular mortality in oral 1alpha-hydroxy vitamin D3 users in a haemodialysis population. Nephrol Dial Transplant 19:179–184PubMedCrossRefGoogle Scholar
  35. 35.
    Teng M, Wolf M, Lowrie E, Ofsthun N, Lazarus JM, Thadhani R (2003) Survival of patients undergoing hemodialysis with paricalcitol or calcitriol therapy. N Engl J Med 349:446–456PubMedCrossRefGoogle Scholar
  36. 36.
    Teng M, Wolf M, Ofsthun MN, Lazarus JM, Hernan MA, Camargo CA Jr, Thadhani R (2005) Activated injectable vitamin D and hemodialysis survival: a historical cohort study. J Am Soc Nephrol 16:1115–1125PubMedCrossRefGoogle Scholar
  37. 37.
    Tentori F, Hunt WC, Stidley CA, Rohrscheib MR, Bedrick EJ, Meyer KB, Johnson HK, Zager PG (2006) Mortality risk among hemodialysis patients receiving different vitamin D analogs. Kidney Int 70:1858–1865PubMedCrossRefGoogle Scholar
  38. 38.
    Thadhani R, Wolf M (2007) Vitamin D in patients with kidney disease: cautiously optimistic. Adv Chronic Kidney Dis 14:22–26PubMedCrossRefGoogle Scholar
  39. 39.
    Wolf M, Shah A, Gutierrez O, Ankers E, Monroy M, Tamez H, Steele D, Chang Y, Camargo CA Jr, Tonelli M, Thadhani R (2007) Vitamin D levels and early mortality among incident hemodialysis patients. Kidney Int 72:1004–1013PubMedCrossRefGoogle Scholar
  40. 40.
    Zittermann A, Koerfer R (2008) Vitamin D in the prevention and treatment of coronary heart disease. Curr Opin Clin Nutr Metab Care 11:752–757PubMedCrossRefGoogle Scholar
  41. 41.
    Zittermann A, Koerfer R (2008) Protective and toxic effects of vitamin D on vascular calcification: clinical implications. Mol Aspects Med 29:423–432PubMedCrossRefGoogle Scholar
  42. 42.
    Wolf M, Thadhani R (2005) Beyond minerals and parathyroid hormone: role of active vitamin D in end-stage renal disease. Semin Dial 18:302–306PubMedCrossRefGoogle Scholar
  43. 43.
    Bodyak N, Ayus JC, Achinger S, Shivalingappa V, Ke Q, Chen YS, Rigor DL, Stillman I, Tamez H, Kroeger PE, Wu-Wong RR, Karumanchi SA, Thadhani R, Kang PM (2007) Activated vitamin D attenuates left ventricular abnormalities induced by dietary sodium in Dahl salt-sensitive animals. Proc Natl Acad Sci USA 104:16810–16815PubMedCrossRefGoogle Scholar
  44. 44.
    Li YC, Kong J, Wei M, Chen ZF, Liu SQ, Cao LP (2002) 1, 25-Dihydroxyvitamin D(3) is a negative endocrine regulator of the renin-angiotensin system. J Clin Invest 110:229–238PubMedGoogle Scholar
  45. 45.
    Lind L, Wengle B, Wide L, Ljunghall S (1989) Reduction of blood pressure during long-term treatment with active vitamin D (alphacalcidol) is dependent on plasma renin activity and calcium status. A double-blind, placebo-controlled study. Am J Hypertens 2:20–25PubMedGoogle Scholar
  46. 46.
    Zittermann A, Schleithoff SS, Koerfer R (2007) Vitamin D and vascular calcification. Curr Opin Lipidol 18:41–46PubMedCrossRefGoogle Scholar
  47. 47.
    Shroff RC, Shanahan CM (2007) The vascular biology of calcification. Semin Dial 20:103–109PubMedCrossRefGoogle Scholar
  48. 48.
    Shroff RC, McNair R, Skepper JN, Figg N, Schurgers LJ, Deanfield J, Rees L, Shanahan CM (2009) Chronic Mineral Dysregulation Promotes Vascular Smooth Muscle Cell Adaptation and Extracellular Matrix Calcification. J Am Soc Nephrol 21:103–112PubMedCrossRefGoogle Scholar
  49. 49.
    Zittermann A, Schleithoff SS, Koerfer R (2005) Putting cardiovascular disease and vitamin D insufficiency into perspective. Br J Nutr 94:483–492PubMedCrossRefGoogle Scholar
  50. 50.
    Cardus A, Parisi E, Gallego C, Aldea M, Fernandez E, Valdivielso JM (2006) 1, 25-Dihydroxyvitamin D3 stimulates vascular smooth muscle cell proliferation through a VEGF-mediated pathway. Kidney Int 69:1377–1384PubMedGoogle Scholar
  51. 51.
    London GM, Guerin AP, Verbeke FH, Pannier B, Boutouyrie P, Marchais SJ, Metivier F (2007) Mineral metabolism and arterial functions in end-stage renal disease: potential role of 25-hydroxyvitamin D deficiency. J Am Soc Nephrol 18:613–620PubMedCrossRefGoogle Scholar
  52. 52.
    Go AS, Chertow GM, Fan D, McCulloch CE, Hsu CY (2004) Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med 351:1296–1305PubMedCrossRefGoogle Scholar
  53. 53.
    Shroff R, Donald A, Hiorns M, Watson A, Feather S, Milford D, Ellins E, Storry C, Deanfield J, Rees L (2007) Parathyroid hormone level and the dose of calcitriol therapy relate to arterial structure and calcification in children on dialysis. J Am Soc Nephrol 18:2996–3003Google Scholar
  54. 54.
    de Boer IH, Kestenbaum B, Shoben AB, Michos ED, Sarnak MJ, Siscovick DS (2009) 25-hydroxyvitamin D levels inversely associate with risk for developing coronary artery calcification. J Am Soc Nephrol 20:1805-1812Google Scholar
  55. 55.
    Shroff R, Egerton M, Bridel M, Shah V, Donald AE, Cole TJ, Hiorns MP, Deanfield JE, Rees L (2008) A bimodal association of vitamin D levels and vascular disease in children on dialysis. J Am Soc Nephrol 19:1239–1246PubMedCrossRefGoogle Scholar
  56. 56.
    Barger-Lux MJ, Heaney RP, Hayes J, Deluca HF, Johnson ML, Gong G (1995) Vitamin D receptor gene polymorphism, bone mass, body size, and vitamin D receptor density. Calcif Tissue Int 57:161–162PubMedCrossRefGoogle Scholar
  57. 57.
    Issa LL, Leong GM, Sutherland RL, Eisman JA (2002) Vitamin D analogue-specific recruitment of vitamin D receptor coactivators. J Bone Miner Res 17:879–890PubMedCrossRefGoogle Scholar
  58. 58.
    Maenpaa PH, Vaisanen S, Jaaskelainen T, Ryhanen S, Rouvinen J, Duchier C, Mahonen A (2001) Vitamin D(3) analogs (MC 1288, KH 1060, EB 1089, GS 1558, and CB 1093): studies on their mechanism of action. Steroids 66:223–225PubMedCrossRefGoogle Scholar
  59. 59.
    Preece MA, McIntosh WB, Tomlinson S, Ford JA, Dunnigan MG, O’Riordan JL (1973) Vitamin-D deficiency among Asian immigrants to Britain. Lancet 1:907–910PubMedCrossRefGoogle Scholar
  60. 60.
    Thomas MK, Lloyd-Jones DM, Thadhani RI, Shaw AC, Deraska DJ, Kitch BT, Vamvakas EC, Dick IM, Prince RL, Finkelstein JS (1998) Hypovitaminosis D in medical inpatients. N Engl J Med 338:777–783PubMedCrossRefGoogle Scholar
  61. 61.
    Heaney RP, Davies KM, Chen TC, Holick MF, Barger-Lux MJ (2003) Human serum 25-hydroxycholecalciferol response to extended oral dosing with cholecalciferol. Am J Clin Nutr 77:204–210PubMedGoogle Scholar
  62. 62.
    Heaney RP, Armas LA, Shary JR, Bell NH, Binkley N, Hollis BW (2008) 25-Hydroxylation of vitamin D3: relation to circulating vitamin D3 under various input conditions. Am J Clin Nutr 87:1738–1742PubMedGoogle Scholar
  63. 63.
    Reusch J, Ackermann H, Badenhoop K (2009) Cyclic changes of vitamin D and PTH are primarily regulated by solar radiation: 5-year analysis of a German (50 degrees N) population. Horm Metab Res 41:402–407PubMedCrossRefGoogle Scholar
  64. 64.
    Belostotsky V, Mughal MZ, Berry JL, Webb NJ (2008) Vitamin D deficiency in children with renal disease. Arch Dis Child 93:959–962PubMedCrossRefGoogle Scholar
  65. 65.
    Andress DL (2008) Bone and mineral guidelines for patients with chronic kidney disease: a call for revision. Clin J Am Soc Nephrol 3:179–183PubMedCrossRefGoogle Scholar
  66. 66.
    Zittermann A, Grant WB (2009) 25-hydroxyvitamin D levels and all-cause mortality. Arch Intern Med 169:1075–1076PubMedCrossRefGoogle Scholar
  67. 67.
    Levin A, Bakris GL, Molitch M, Smulders M, Tian J, Williams LA, Andress DL (2007) Prevalence of abnormal serum vitamin D, PTH, calcium, and phosphorus in patients with chronic kidney disease: results of the study to evaluate early kidney disease. Kidney Int 71:31–38PubMedCrossRefGoogle Scholar
  68. 68.
    Sato KA, Gray RW, Lemann J Jr (1982) Urinary excretion of 25-hydroxyvitamin D in health and the nephrotic syndrome. J Lab Clin Med 99:325–330PubMedGoogle Scholar
  69. 69.
    Clements MR, Johnson L, Fraser DR (1987) A new mechanism for induced vitamin D deficiency in calcium deprivation. Nature 325:62–65PubMedCrossRefGoogle Scholar
  70. 70.
    Nykjaer A, Dragun D, Walther D, Vorum H, Jacobsen C, Herz J, Melsen F, Christensen EI, Willnow TE (1999) An endocytic pathway essential for renal uptake and activation of the steroid 25-(OH) vitamin D3. Cell 96:507–515PubMedCrossRefGoogle Scholar
  71. 71.
    Menon S, Valentini RP, Hidalgo G, Peschansky L, Mattoo TK (2008) Vitamin D insufficiency and hyperparathyroidism in children with chronic kidney disease. Pediatr Nephrol 23:1831–1836PubMedCrossRefGoogle Scholar
  72. 72.
    Seeherunvong W, Abitbol CL, Chandar J, Zilleruelo G, Freundlich M (2009) Vitamin D insufficiency and deficiency in children with early chronic kidney disease. J Pediatr 154:906–911PubMedCrossRefGoogle Scholar
  73. 73.
    Smotkin-Tangorra M, Purushothaman R, Gupta A, Nejati G, Anhalt H, Ten S (2007) Prevalence of vitamin D insufficiency in obese children and adolescents. J Pediatr Endocrinol Metab 20:817–823PubMedGoogle Scholar
  74. 74.
    Groothoff JW, Gruppen MP, Offringa M, Hutten J, Lilien MR, Van De Kar NJ, Wolff ED, Davin JC, Heymans HS (2002) Mortality and causes of death of end-stage renal disease in children: a Dutch cohort study. Kidney Int 61:621–629PubMedCrossRefGoogle Scholar
  75. 75.
    Autier P, Gandini S (2007) Vitamin D supplementation and total mortality: a meta-analysis of randomized controlled trials. Arch Intern Med 167:1730–1737PubMedCrossRefGoogle Scholar
  76. 76.
    Wolf M, Thadhani R (2007) Vitamin D in patients with renal failure: a summary of observational mortality studies and steps moving forward. J Steroid Biochem Mol Biol 103:487–490PubMedCrossRefGoogle Scholar
  77. 77.
    Barreto DV, Barreto FC, Liabeuf S, Temmar M, Boitte F, Choukroun G, Fournier A, Massy ZA (2009) Vitamin D affects survival independently of vascular calcification in chronic kidney disease. Clin J Am Soc Nephrol 4:1128–1135PubMedCrossRefGoogle Scholar
  78. 78.
    Tentori F, Albert JM, Young EW, Blayney MJ, Robinson BM, Pisoni RL, Akiba T, Greenwood RN, Kimata N, Levin NW, Piera LM, Saran R, Wolfe RA, Port FK (2009) The survival advantage for haemodialysis patients taking vitamin D is questioned: findings from the Dialysis Outcomes and Practice Patterns Study. Nephrol Dial Transplant 24:963–972PubMedCrossRefGoogle Scholar
  79. 79.
    Palmer SC, McGregor DO, Macaskill P, Craig JC, Elder GJ, Strippoli GF (2007) Meta-analysis: vitamin D compounds in chronic kidney disease. Ann Intern Med 147:840–853PubMedGoogle Scholar
  80. 80.
    Wagner CL, Greer FR (2008) Prevention of rickets and vitamin D deficiency in infants, children, and adolescents. Pediatrics 122:1142–1152PubMedCrossRefGoogle Scholar
  81. 81.
    Vieth R, Bischoff-Ferrari H, Boucher BJ, Dawson-Hughes B, Garland CF, Heaney RP, Holick MF, Hollis BW, Lamberg-Allardt C, McGrath JJ, Norman AW, Scragg R, Whiting SJ, Willett WC, Zittermann A (2007) The urgent need to recommend an intake of vitamin D that is effective. Am J Clin Nutr 85:649–650PubMedGoogle Scholar
  82. 82.
    Pepper KJ, Judd SE, Nanes MS, Tangpricha V (2009) Evaluation of vitamin D repletion regimens to correct vitamin D status in adults. Endocr Pract 15:95–103PubMedGoogle Scholar
  83. 83.
    Pietras SM, Obayan BK, Cai MH, Holick MF (2009) Vitamin D2 treatment for vitamin D deficiency and insufficiency for up to 6 years. Arch Intern Med 169:1806–1808PubMedCrossRefGoogle Scholar
  84. 84.
    Grant WB, Cross HS, Garland CF, Gorham ED, Moan J, Peterlik M, Porojnicu AC, Reichrath J, Zittermann A (2009) Estimated benefit of increased vitamin D status in reducing the economic burden of disease in western Europe. Prog Biophys Mol Biol 99:104–113PubMedCrossRefGoogle Scholar
  85. 85.
    KDOQI Work Group (2009) KDOQI Clinical Practice Guideline for Nutrition in Children with CKD: 2008 update. Executive summary. Am J Kidney Dis (3 Suppl 2):S11–S104Google Scholar
  86. 86.
    Armas LA, Hollis BW, Heaney RP (2004) Vitamin D2 is much less effective than vitamin D3 in humans. J Clin Endocrinol Metab 89:5387–5391PubMedCrossRefGoogle Scholar
  87. 87.
    Al-Aly Z, Qazi RA, Gonzalez EA, Zeringue A, Martin KJ (2007) Changes in serum 25-hydroxyvitamin D and plasma intact PTH levels following treatment with ergocalciferol in patients with CKD. Am J Kidney Dis 50:59–68PubMedCrossRefGoogle Scholar
  88. 88.
    Zisman AL, Hristova M, Ho LT, Sprague SM (2007) Impact of ergocalciferol treatment of vitamin D deficiency on serum parathyroid hormone concentrations in chronic kidney disease. Am J Nephrol 27:36–43PubMedCrossRefGoogle Scholar
  89. 89.
    DeVille J, Thorp ML, Tobin L, Gray E, Johnson ES, Smith DH (2006) Effect of ergocalciferol supplementation on serum parathyroid hormone and serum 25-hydroxyvitamin D in chronic kidney disease. Nephrology (Carlton) 11:555–559CrossRefGoogle Scholar
  90. 90.
    Dogan E, Erkoc R, Sayarlioglu H, Soyoral Y, Dulger H (2008) Effect of depot oral cholecalciferol treatment on secondary hyperparathyroidism in stage 3 and stage 4 chronic kidney diseases patients. Ren Fail 30:407–410PubMedCrossRefGoogle Scholar
  91. 91.
    Chandra P, Binongo JN, Ziegler TR, Schlanger LE, Wang W, Someren JT, Tangpricha V (2008) Cholecalciferol (vitamin D3) therapy and vitamin D insufficiency in patients with chronic kidney disease: a randomized controlled pilot study. Endocr Pract 14:10–17PubMedGoogle Scholar
  92. 92.
    Oksa A, Spustova V, Krivosikova Z, Gazdikova K, Fedelesova V, Lajdova I, Stefikova K, Bernasovska G, Zilinska Z, Dzurik R (2008) Effects of long-term cholecalciferol supplementation on mineral metabolism and calciotropic hormones in chronic kidney disease. Kidney Blood Press Res 31:322–329PubMedCrossRefGoogle Scholar
  93. 93.
    Rucker D, Tonelli M, Coles MG, Yoo S, Young K, McMahon AW (2009) Vitamin D insufficiency and treatment with oral vitamin D3 in northern-dwelling patients with chronic kidney disease. J Nephrol 22:75–82PubMedGoogle Scholar
  94. 94.
    Belostotsky V, Mughal Z, Webb NJ (2009) A single high dose of ergocalciferol can be used to boost 25-hydroxyvitamin D levels in children with kidney disease. Pediatr Nephrol 24:625–626PubMedCrossRefGoogle Scholar
  95. 95.
    National Kidney Foundation (2003) K/DOQI Clinical Practice Guidelines for Bone Metabolism and Disease in Chronic Kidney Disease. Am J Kidney Dis (4 Suppl 3):S1–S201Google Scholar
  96. 96.
    Berl T, Berns AS, Hufer WE, Hammill K, Alfrey AC, Arnaud CD, Schrier RW (1978) 1, 25 dihydroxycholecalciferol effects in chronic dialysis. A double-blind controlled study. Ann Intern Med 88:774–780PubMedGoogle Scholar
  97. 97.
    Malluche HH, Ritz E, Werner E, Meyer-Sabellek WA (1978) Long-term administration of vitamin D steroles in incipient and advanced renal failure: effect on bone histology. Clin Nephrol 10:219–228PubMedGoogle Scholar
  98. 98.
    Jean G, Terrat JC, Vanel T, Hurot JM, Lorriaux C, Mayor B, Chazot C (2008) Evidence for persistent vitamin D 1-alpha-hydroxylation in hemodialysis patients: evolution of serum 1, 25-dihydroxycholecalciferol after 6 months of 25-hydroxycholecalciferol treatment. Nephron Clin Pract 110:c58–c65PubMedCrossRefGoogle Scholar
  99. 99.
    Jean G, Souberbielle JC, Chazot C (2009) Monthly cholecalciferol administration in haemodialysis patients: a simple and efficient strategy for vitamin D supplementation. Nephrol Dial Transplant 24:3799–3805PubMedCrossRefGoogle Scholar
  100. 100.
    Blair D, Byham-Gray L, Lewis E, McCaffrey S (2008) Prevalence of vitamin D [25(OH)D] deficiency and effects of supplementation with ergocalciferol (vitamin D2) in stage 5 chronic kidney disease patients. J Ren Nutr 18:375–382PubMedCrossRefGoogle Scholar
  101. 101.
    Saab G, Young DO, Gincherman Y, Giles K, Norwood K, Coyne DW (2007) Prevalence of vitamin D deficiency and the safety and effectiveness of monthly ergocalciferol in hemodialysis patients. Nephron Clin Pract 105:c132–c138PubMedGoogle Scholar
  102. 102.
    Gallieni M, Kamimura S, Ahmed A, Bravo E, Delmez J, Slatopolsky E, Dusso A (1995) Kinetics of monocyte 1 alpha-hydroxylase in renal failure. Am J Physiol 268:F746–F753PubMedGoogle Scholar
  103. 103.
    Kerr DN (1997) Hypercalcemia and metastatic calcification. Cardiovasc Res 36:293–297PubMedCrossRefGoogle Scholar
  104. 104.
    Markestad T, Hesse V, Siebenhuner M, Jahreis G, Aksnes L, Plenert W, Aarskog D (1987) Intermittent high-dose vitamin D prophylaxis during infancy: effect on vitamin D metabolites, calcium, and phosphorus. Am J Clin Nutr 46:652–658PubMedGoogle Scholar
  105. 105.
    Blank S, Scanlon KS, Sinks TH, Lett S, Falk H (1995) An outbreak of hypervitaminosis D associated with the overfortification of milk from a home-delivery dairy. Am J Public Health 85:656–659PubMedCrossRefGoogle Scholar
  106. 106.
    Vieth R (1990) The mechanisms of vitamin D toxicity. Bone Miner 11:267–272PubMedCrossRefGoogle Scholar
  107. 107.
    Heaney RP (2009) Optimal vitamin D status. J Bone Miner Res 24:755PubMedCrossRefGoogle Scholar
  108. 108.
    Hathcock JN, Shao A, Vieth R, Heaney R (2007) Risk assessment for vitamin D. Am J Clin Nutr 85:6–18PubMedGoogle Scholar
  109. 109.
    Mawer EB, Schaefer K, Lumb GA, Stanbury SW (1971) The metabolism of isotopically labelled vitamin D3 in man: the influence of the state of vitamin D nutrition. Clin Sci 40:39–53PubMedGoogle Scholar
  110. 110.
    Littledike ET, Horst RL (1982) Metabolism of vitamin D3 in nephrectomized pigs given pharmacological amounts of vitamin D3. Endocrinology 111:2008–2013PubMedCrossRefGoogle Scholar
  111. 111.
    Littledike ET, Horst RL (1982) Vitamin D3 toxicity in dairy cows. J Dairy Sci 65:749–759PubMedCrossRefGoogle Scholar
  112. 112.
    Pettifor JM, Bikle DD, Cavaleros M, Zachen D, Kamdar MC, Ross FP (1995) Serum levels of free 1, 25-dihydroxyvitamin D in vitamin D toxicity. Ann Intern Med 122:511–513PubMedGoogle Scholar
  113. 113.
    Shephard RM, Deluca HF (1980) Plasma concentrations of vitamin D3 and its metabolites in the rat as influenced by vitamin D3 or 25-hydroxyvitamin D3 intakes. Arch Biochem Biophys 202:43–53PubMedCrossRefGoogle Scholar
  114. 114.
    Selby PL, Davies M, Marks JS, Mawer EB (1995) Vitamin D intoxication causes hypercalcaemia by increased bone resorption which responds to pamidronate. Clin Endocrinol (Oxf) 43:531–536CrossRefGoogle Scholar

Copyright information

© IPNA 2010

Authors and Affiliations

  1. 1.Department of Nephrology, Great Ormond Street Hospital for ChildrenNHS TrustLondonUK

Personalised recommendations